Tumour-infiltrating lymphocytes
Revision as of 16:05, 25 June 2021 by Michael (talk | contribs) (→Tumours with abundant lymphocytes as a component)
Tumour-infiltrating lymphocytes. H&E stain.
Tumour-infiltrating lymphocytes, abbreviated TILs, is the presence of many lymphoctyes between tumour cells.
TILs in the context of colorectal carcinoma are dealt with in intratumoural lymphocytic response in colorectal carcinoma.
General
Common finding in a large number of tumours:
| Tumour | Association |
|---|---|
| Colorectal carcinoma | TILs in CRC are associated with microsatellite instability[1] |
| Malignant melanoma | TILs better survival[2] |
| Non-small cell lung cancer | TILs associated with anti-PD-L1 response[3] |
| Ovarian serous carcinoma | TILs associated with good prognosis[4] |
Tumours with abundant lymphocytes as a component
- Nasopharyngeal carcinoma.
- Lymphoepithelioma-like carcinoma.
- Thymoma.
- Follicular dendritic cell sarcoma.
- Seminoma.
- Others.
See also
- PD-L1.
- Intratumoural lymphocytic response in colorectal carcinoma.
- Peritumoural lymphocytic response (Crohn's like reaction).
- Intraepithelial lymphocytes.
References
- ↑ Iacopetta, B.; Grieu, F.; Amanuel, B. (Dec 2010). "Microsatellite instability in colorectal cancer.". Asia Pac J Clin Oncol 6 (4): 260-9. doi:10.1111/j.1743-7563.2010.01335.x. PMID 21114775.
- ↑ Lee, N.; Zakka, LR.; Mihm, MC.; Schatton, T. (Feb 2016). "Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.". Pathology 48 (2): 177-87. doi:10.1016/j.pathol.2015.12.006. PMID 27020390.
- ↑ Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D. et al. (Mar 2016). "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.". Lancet. doi:10.1016/S0140-6736(16)00587-0. PMID 26970723.
- ↑ Webb, JR.; Milne, K.; Kroeger, DR.; Nelson, BH. (May 2016). "PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.". Gynecol Oncol 141 (2): 293-302. doi:10.1016/j.ygyno.2016.03.008. PMID 26972336.